Together with the finding that experimental blockage with the antiviral drug ganciclovir alleviated EAE by decreasing microglial reactivity in a STING/type I IFN-dependent fashion [32], these data suggest this pathway as a novel target for treating MS. This evidence concerns the gene STING1 and myeloid sarcoma.